Raleigh Capital Management Inc. Increases Position in Medtronic PLC $MDT

Raleigh Capital Management Inc. grew its position in shares of Medtronic PLC (NYSE:MDT) by 306.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,528 shares of the medical technology company’s stock after purchasing an additional 10,198 shares during the quarter. Raleigh Capital Management Inc.’s holdings in Medtronic were worth $1,172,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. CSM Advisors LLC increased its holdings in shares of Medtronic by 13.2% in the third quarter. CSM Advisors LLC now owns 285,260 shares of the medical technology company’s stock worth $27,169,000 after buying an additional 33,167 shares during the period. SageView Advisory Group LLC lifted its stake in shares of Medtronic by 164.8% in the 3rd quarter. SageView Advisory Group LLC now owns 24,204 shares of the medical technology company’s stock valued at $2,305,000 after acquiring an additional 15,062 shares during the last quarter. Madison Asset Management LLC boosted its holdings in Medtronic by 15.0% during the 4th quarter. Madison Asset Management LLC now owns 195,216 shares of the medical technology company’s stock valued at $18,752,000 after acquiring an additional 25,527 shares during the period. Ticino Wealth purchased a new stake in Medtronic during the 4th quarter valued at about $2,049,000. Finally, First Eagle Investment Management LLC grew its position in Medtronic by 0.4% during the 4th quarter. First Eagle Investment Management LLC now owns 9,775,234 shares of the medical technology company’s stock worth $939,009,000 after acquiring an additional 40,196 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors.

Insider Activity at Medtronic

In related news, EVP Harry Skip Kiil sold 4,189 shares of Medtronic stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.44, for a total transaction of $336,963.16. Following the sale, the executive vice president directly owned 37,227 shares in the company, valued at $2,994,539.88. The trade was a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.26% of the stock is currently owned by insiders.

Analyst Ratings Changes

MDT has been the subject of a number of analyst reports. BTIG Research raised Medtronic from a “neutral” rating to a “buy” rating and set a $90.00 price objective for the company in a research note on Wednesday, June 3rd. JPMorgan Chase & Co. decreased their target price on shares of Medtronic from $100.00 to $86.00 and set a “neutral” rating on the stock in a research note on Thursday, June 4th. Sanford C. Bernstein lowered their price target on shares of Medtronic from $112.00 to $97.00 and set an “outperform” rating for the company in a report on Thursday, June 4th. Rothschild & Co Redburn dropped their price target on shares of Medtronic from $111.00 to $106.00 and set a “buy” rating for the company in a research report on Friday, June 5th. Finally, Deutsche Bank Aktiengesellschaft cut their price target on shares of Medtronic from $100.00 to $78.00 and set a “hold” rating on the stock in a report on Thursday, June 4th. Seventeen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $99.00.

Medtronic Price Performance

Shares of NYSE MDT opened at $83.07 on Friday. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33. The stock has a market capitalization of $106.33 billion, a P/E ratio of 22.27, a P/E/G ratio of 2.23 and a beta of 0.56. The company’s 50-day moving average is $79.04 and its 200 day moving average is $89.06. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, topping the consensus estimate of $1.54 by $0.01. The business had revenue of $9.81 billion during the quarter, compared to analyst estimates of $9.62 billion. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. Medtronic’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period last year, the business posted $1.62 earnings per share. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, sell-side analysts expect that Medtronic PLC will post 5.94 earnings per share for the current year.

Medtronic Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 17th. Stockholders of record on Friday, June 26th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.5%. The ex-dividend date is Friday, June 26th. This is a boost from Medtronic’s previous quarterly dividend of $0.71. Medtronic’s dividend payout ratio (DPR) is 77.21%.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Investors continue to reward Medtronic’s stronger-than-expected fiscal Q4 results and improved fiscal 2027 outlook, which included solid revenue growth and guidance that supports a more constructive growth narrative for the stock.
• Positive Sentiment: Medtronic expanded its partnership with Retia Medical to distribute the Argos cardiac output monitor more broadly, supporting growth in high-acuity cardiovascular and critical-care markets and reinforcing the company’s expansion into higher-growth device categories. Article Title
• Positive Sentiment: Analyst sentiment remains favorable, with recent coverage showing a “Moderate Buy” tone and several firms maintaining bullish ratings, which may be helping support the share price. Article Title
• Neutral Sentiment: Articles discussing why MDT is up since its last earnings report suggest the move may be a continuation of post-earnings buying rather than a reaction to a fresh catalyst, indicating momentum more than a new surprise. Article Title
• Neutral Sentiment: Medtronic has begun notifying people affected by a cyberattack, but the company said there is no evidence the accessed data was posted online and no impact to patient safety or core operations has been identified so far. Article Title
• Negative Sentiment: The cybersecurity incident still introduces headline risk and potential reputational or legal concerns, even though Medtronic says the event has not affected operations.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).